TSX:TH - Toronto Stock Exchange - CA88338H7040 - Common Stock - Currency: CAD
THERATECHNOLOGIES INC
TSX:TH (2/5/2025, 7:00:00 PM)
2.18
+0.04 (+1.87%)
The current stock price of TH.CA is 2.18 CAD. In the past month the price decreased by -24.31%. In the past year, price decreased by -0.46%.
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...
MONTRÉAL, 09 janv. 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une...
MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...
MONTRÉAL, 18 déc. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 286.42M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 267.56M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 161.22M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 156.37M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 95.36M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 27.36 | 82.47M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 80.92M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 80.27M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 16.67 | 67.27M | ||
SVA.CA | SERNOVA CORP | N/A | 56.39M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 44.12M | ||
MDCX.CA | MEDICUS PHARMA LTD | N/A | 41.77M |
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 103 full-time employees. The firm is focused on the development and commercialization of therapies addressing unmet medical needs. The company markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The firm's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
THERATECHNOLOGIES INC
2015 Peel Street, 11th Floor
MONTREAL QUEBEC H3A 1T8 CA
CEO: Paul Levesque
Employees: 103
Company Website: https://www.theratech.com/
Investor Relations: https://www.theratech.com/investors/
Phone: 15143367800
The current stock price of TH.CA is 2.18 CAD.
The exchange symbol of THERATECHNOLOGIES INC is TH and it is listed on the Toronto Stock Exchange exchange.
TH.CA stock is listed on the Toronto Stock Exchange exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TH.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TH.CA.
TH.CA does not pay a dividend.
TH.CA will report earnings on 2025-02-19, after the market close.
TH.CA does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).
ChartMill assigns a technical rating of 3 / 10 to TH.CA. When comparing the yearly performance of all stocks, TH.CA turns out to be only a medium performer in the overall market: it outperformed 65.19% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to TH.CA. TH.CA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months TH.CA reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS decreased by 91.87% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -4.53% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 84% to TH.CA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 103.61% and a revenue growth 1.81% for TH.CA